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Among the dendritic cell (DC) subsets, plasmacytoid DC’s (pDC) are thought to be important in the generation of
both antiviral and antitumor responses. While pDC may be useful in developing dendritic cell-based tumor
vaccines, the low frequency of these cells in the peripheral blood has hampered attempts to understand their
biology. To provide better insight into the biology of pDC, we isolated these unperturbed cells from the peripheral
blood of healthy donors in order to further characterize their gene expression. Using gene array technology we
compared the genetic profiles of these cells to those of CD14+ monocytes isolated from the same donors and
found several immune related genes upregulated in this cell population. This is the first description, to our
knowledge, of gene expression in this subset of DCs obtained from the peripheral blood of adult human donors
without exposure in vitro to cytokine or growth factors. Understanding the natural genetic profiles of this dendritic
cell subtype as well as others such as the BDCA-1 expressing myeloid DCs may enable us to manipulate these cells
ex-vivo to generate enhanced DC-based tumor vaccines inducing more robust antitumor responses.
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Dendritic cells are paramount in generating cell-mediated
and humoral immune responses and have been utilized for
cancer vaccines against melanoma, prostate cancer, renal
cell carcinoma, and non-Hodgkin’s lymphoma with varying
results, including an FDA approved therapy for prostate
cancer patients [1-5]. The DC’s used in many of these trials
are generated from a heterogenous group of immature
peripheral blood DC’s and CD14+ cells obtained from can-
cer patients. These cells are expanded ex vivo in the pres-
ence of GM-CSF and Interleukin-4, subjected to antigen
loading, maturation and subsequently reintroduced into the
donor. The heterogeneity of the DCs confounds the overall
results observed in the patients’ antitumor responses in
these trials.
Although there can be plasticity of function between
DC subtypes [6], in general, myeloid DCs (mDC) and* Correspondence: swrzesinski@sphcs.org
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distribution, and reproduction in any mediumplasmacytoid DCs (pDC) are considered to induce
cell-mediated (TH1 type) and humoral (TH2) responses
respectively. Blood DC antigen (BDCA) 1 and 4 are pre-
ferentially expressed on mDC and pDC respectively and
can be exploited to isolate pure populations of these cell
types [7]. While mDC have been characterized both in
healthy donors and cancer patients [8], the low frequency
of pDC in the peripheral blood compartment has prevented
extensive evaluations of this cell population. Little is known
about the de novo state of pDC. Until recently [9], periph-
eral blood pDC have not been well-characterized and the
biology of these cells has been established using either mur-
ine or human cells expanded in culture from CD34+ pre-
cursors [10]. Because of their ability to produce high levels
of type I (α and β) interferons, pDC are thought to play a
role in augmenting antiviral responses [11]. More recently
these cells have also been demonstrated to synergize with
mDCs to induce antigen-specific antitumor responses
against ova-expressing murine thymomas [12] and basal
cell cancers [13]. These studies suggest that initiating DC
expansion from pure DC precursors (pDCs or mDCs)
would be an attractive strategy for human DC vaccinetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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subsets could help to determine the optimal use of these
cells in tumor vaccine studies. Therefore, we isolated and
evaluated the gene expression profiles of human pDCs.Materials and methods
pDC isolation and purification by MACS and FACS
After signing consent per Protocol D9726 (Committee for
the Protection of Human Subjects#12756), healthy adult
donors were tested for viral serologies (HIV, Hepatitis)
and underwent leukapheresis using a Cobe Spectra Apher-
esis System (Lakewood, CO) if viral titers were negative.
Each leukopak was then subjected to Ficol-gradient isola-
tion and resulting peripheral blood mononuclear cells
(PBMC) were stored in RPMI containing autologous
serum overnight at 4°C.
The following day 1.1 x 109 donor PBMC were stained
with defined iron-conjugated antibodies and magnetically
sorted as per Miltenyi Biotec protocol on the autoMACS.
(Miltneyi Biotec, Auburn CA). The labeled cells were
subjected to FACS using a FACStar Plus cytometer by
pre-gating on the subset of CD3- and CD20- cells, and
then gating on the BDCA-4 positive cells in this subset.
Cell populations with at least 95% purity by FACS analysis
were used for subsequent experiments.Gene array evaluation of BDCA-4 cells and confirmation
of upregulated genes by RT-PCR
RNA was extracted using the Quiagen RNeasy method
(Quiagen, Valencia, CA). The RNA was subsequently
labeled and hybridized to the HU133A gene chip using
the method established by Affymetrix and run on the
Affymetrix system (Affymetrix, Santa Clara, CA). The
gene expression data was subjected to analysis by the
Iobion Gene Traffic W software as described below.
Changes in expression levels of genes of interest were
confirmed by RT-PCR using RNA extracted from two of
the isolated BDCA-4+ DC cell samples and the autologous
CD14+ cell samples used for the gene array comparisons.
In brief, RNA was isolated from FACS sorted BDCA-4
and CD14 positive cells using standard Qiagen-RNeasy
protocol. RNA was eluted with 30 μl of RNase-free water
and stored at −80°C. The cDNA was synthesized using
iscript cDNA kit (Bio-Rad, Hercules, CA). The Medline
database was used to obtain mRNA gene sequences.
Primers for all of the upregulated genes confirmed by
RT-PCR (ie, Granzyme B, Chemokine like receptor 1,
TLR-7) were designed using Primer3 Output, an on-
line primer-design program. Primer sequences were as
follows:
TLR7 forward AAT GTC ACA GCC GTC CCT AC
TLR7 reverse TTA TTT TTA CAC GGC GCA CAGZMB forward ATG CAA CCA ATC CTG CTT CT
GZMB reverse TTA TGG AGC TTC CCC AAC AG
Cmklr1 forward CGT CTT CCT CCC AAT CCA TA
Cmklr1 reverse AAG AAA GCC AGG ACC CAG AT
My iQ Single Color Real-Time PCR Detection system
was used to perform real-time RT-PCR (Bio-Rad, Hercules,
CA). Amplification of β-actin was used as an endogenous
reference gene.
Data analysis
CellQuest software was used to analyze the purity of the
BDCA-4 cells obtained by MACS and FACS.
Differential gene expression was evaluated by Iobion Gene
Traffic W software by using differential gene expression of
greater than or less then 3 fold between groups [14] as de-
scribed below. CD14 monocytes obtained from the same
donor served as the baseline gene array profile for all ana-
lyses (see Gene Expression Omnibus [GEO] GSE11943 for
full sets of gene array data).
Affymetrix image and data files were directly imported in
GeneTraffic Uno Microarray Data Management and Ana-
lysis Software Version 3.2, Iobion Informatics LLC, La Jolla,
CA. Data was normalized by transforming with Robust
Multichip Analysis (RMA) [15]. Fold change values were
generated by comparing BDCA-4 chips to CD14 chips
from the same donor. The dataset was filtered to remove
genes without at least one instance of expression change
that was greater than or less than an absolute fold change
value of 3 across 4 separate gene arrays (one array per four
separate BDCA-4 cell isolations). The resulting genes were
analyzed using Significance Analysis of Microarrays (SAM)
[16] to determine reproducibility across replicates as well as
identify significant expression changes between cell types.
Using a two-class paired test with a significance cutoff of
0.001%, 1232 genes were identified that were significantly
up or down-regulated when compared to CD14 cells.
Subsets of differentially expressed genes were further an-
alyzed using Onto-Express [17] to identify significantly
represented ontology groups.
Results/discussion
We utilized the cell-specific surface expression of
BDCA-4 antigens on pDCs to reproducibly obtain
these populations at greater than 95% purity using
MACS followed by FACS (Figure 1C). FACS sorting
for BDCA-4+ cells not co-expressing the B cell marker
CD20 or the T cell marker, CD3, eliminated contamin-
ating lymphocytes retained following the first isolation
(Figures 1A and 1B).
Gene arrays to evaluate the gene expression in DC’s du-
ring maturation in vitro have revealed upregulation of
genes involved in cell adhesion and motility, immune re-
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Figure 1 Separation of BDCA-4 subpopulation by MACS and
FACS. Representative Flow Cytometry plot evaluating the purity of
BDCA-4 populations from Ficol-separated PBMCs obtained from
normal healthy donors. Leukocytes stained with BDCA-4-PE and the
lymphocyte markers CD3-FITC and CD20-FITC and evaluated by flow
cytometry: Prior to sorting (A), after Magnetic Bead Sorting (MACS)
(B), and after MACS followed by Fluorescence-Activated Cell Sorting
(FACS) (C). R2 indicates the left upper quadrant sorting gate, R3
indicates gate for lymphocytes removed by FACS.
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nel activities and membrane function [18-20]. More re-
cently Lindstedt et al. published the gene family clustering
of human blood and tonsillar DC subsets from healthy
children undergoing tonsillectomy using Affymetrix
gene arrays [21]. We chose the Affymetrix system to as-
sess gene profiles of pure populations of unstimulated
de novo BDCA-4 cells obtained from consented healthy
adult donors.
While gene arrays of DC’s have been compared to several
immune cells, including T-lymphocytes, B-lymphocytes
and macrophages [18], we compared the genetic profiles of
four separate isolations of BDCA-4+ cells from healthy do-
nors to CD14+ cells devoid of BDCA-4 cells as this cell
population is commonly used as DC precursors in cancervaccine trials. Out of over 22,000 genes assessed between
both populations of cells, 448 genes including the BDCA-4
gene were upregulated at least three-fold compared to
those expressed in CD14+ cells (see GSE11943 for gene
array datasets). While the majority of the genes encoded
proteins of unknown function, the remaining upregulated
genes involved several biologic processes including the im-
mune response, cell proliferation, development, protein
amino acid phosphorylation, metabolism, the ubquitin
cycle, cell cycle, transcription and signal transduction path-
ways (Figure 2A). Nineteen of these genes were involved
in the immune and inflammatory response (Figure 2B).
Interestingly, the Granzyme B gene was overexpressed
over 200-fold in all four BDCA-4 cell samples with RT
PCR confirming an 18,000 to 25,000 fold upregulated ex-
pression of this gene relative to CD14 cells (Figure 2B).
Granzyme-B is expressed by innate and adaptive immune
effector cells and plays key roles in the destruction of
tumor cells and cells infected with intracellular pathogens
such as viruses [22]. Rissoan et al. identified high levels
of mRNA expression in both resting and activated pDC
obtained from cord blood and tonsillar tissue [23] and
this enzyme is upregulated by a pDC leukemia [24]. Our
results reinforce the recently published data reported by
Tel J et al. which indicates that this DC cell subtype can be
skewed as a killer DC subset when exposed to viral vaccines
[25]. The gene array data demonstrating overexpression of
Granzyme B at baseline suggests a genetic potential for
effector function by pDC in vivo.
Our data demonstrate unique immune-related genes
expressed in adult peripheral blood plasmacytoid dendritic
cell subtypes relative to autologous CD14 monocytes and
complement the previously reported differential gene ex-
pression of DC subsets obtained from the peripheral blood
and tonsils of children [21].
Interestingly, we found a slightly different pDC gene
expression profile compared to that reported by
Lindstedt et al. While our results also demonstrate sev-
eral immune-related genes upregulated in this subset in-
cluding IL18R1, IL3RA (CD123) and TLR-7, additional
upregulated genes not reported by Lindstedt et al. in-
cluded the leukocyte-associated immunoglobulin like re-
ceptor, IL-18 receptor accessory protein, and lymphotoxin
beta. One limitation of our study was that with the human
HU133A chip we could not assess the previously dem-
onstrated upregulated genes CXCR3, CLECSF7 and
TLR-9 genes [21].
There are a number of reasons to explain why our results
differ from those previously published. First, we used the
more stringent cutoff of greater than or equal to three-fold
up- or down-regulation in our analyses to further eliminate
potential gene signal noise while Lindstedt et al. used ≥
two-fold [21]. Also, the pDC used in Lindstedt’s study were
obtained from children who underwent tonsillectomies [21]
A.  Biologic Processes of BDCA- Upregulated Genes (448 total) 
Immune/Inflammatory Response (19 genes) 
Granzyme B ** (18,306, 24,662) 
Spondin 2 
Chemokine like receptor 1 ** (7.34, 9.23) 
Fc of IgE  
PRKRA (protein kinase, interferon-inducible double stranded RNA dependent 
activator) 
Immunoglobulin kappa constant 





Ig Heavy Chain 
Lymphotoxin Beta 
TNFR Member 4 
CD164, sialomucin 
TLR-7 ** (4.5, 7.6) 
CCR-5 
IL18R1 
IL18 Receptor Accessory protein 
B.  Specific Genes Upregulated in BDCA-4 relative to CD14 cells   
Figure 2 Summary of BDCA-4 dendritic cell genes upregulated (A) and genes involved in the immune response. (A) Biologic processes
of genes upregulated at least three fold using the OntoExpress software as discussed in the materials and methods section. (B) List of specific
genes upregulated in BDCA-4 cells relative to CD14+ cells. ** Genes confirmed to be upregulated using RT-PCR as discussed in the materials and
methods section. Numbers in parentheses indicate two separate values of fold upregulation of the selected upregulated genes confirmed
by RT-PCR.
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adults. Aging can affect both the phenotype and the
function of human monocytes and leukocytes [26]. Add-
itionally, cord blood-derived monocytes and adult mono-
cytes have been demonstrated to have differential gene
profiles at rest and when stimulated with LPS [27].
Therefore it is conceivable that the unstimulated pDC
from our older adult donors would express different
levels of immune-related genes when compared to the
same subtypes obtained from children undergoing
tonsillectomies.
In summary, we have utilized FACS and MACS to
successfully isolate highly purified populations of pDC
from healthy donors and present the genetic signaturesof these cells. We have identified several upregulated
genes in pDC when compared to the CD14+ monocytes
with the gene encoding the effector enzyme, Granzyme
B, being the most upregulated in our isolated pDC,
suggesting an effector function of these cells in the per-
ipheral blood of healthy adults. The genetic profiles
from the pDC in our studies differed from those pub-
lished by Lindstedt et al. This may be due to a combi-
nation of setting different cutoff points for considering
significant up- and down-regulation of gene expression as
well as using cells obtained from older donors. Our re-
sults yield further information regarding unstimulated
pDCs de novo providing an additional foundation for de-
veloping human DC tumor vaccines.
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